Competitive Comparison of Nurix Therapeutics's Profitability Rank
For the Biotechnology subindustry, Nurix Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nurix Therapeutics's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nurix Therapeutics's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Nurix Therapeutics's Profitability Rank falls into.
Nurix Therapeutics Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Nurix Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Nurix Therapeutics's Operating Margin % for the quarter that ended in Feb. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Nurix Therapeutics has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Nurix Therapeutics Inc operating margin has been in a 5-year decline. The average rate of decline per year is -58%.
4. Consistency of the profitability
5. Predictability Rank
Nurix Therapeutics (Nurix Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
1700 Owens Street, Suite 205, San Francisco, CA, USA, 94158
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Executives
| Houte Hans Van |
officer: Chief Financial Officer |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Christine Ring |
officer: General Counsel |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Gwenn Hansen |
officer: Chief Scientific Officer |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Stefani Wolff |
officer: EVP and COO |
C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080 |
| Edward C Saltzman |
director |
C/O NURIX THERAPEUTICS, 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Paul M Silva |
director |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139 |
| Judith A Reinsdorf |
director |
C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
| Pierre Beaurang |
officer: Chief Business Officer |
C/O NURIX THERAPEUTICS, INC., 1700 OWENS STREET, SUITE 205, SAN FRANCISCO CA 94158 |
| Clay B Siegall |
director |
21823 30TH DR SE, BOTHELL WA 98021 |
| Ponoi Capital, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Ponoi Ii Management, Llc |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
| Ponoi Capital Ii, Lp |
10 percent owner |
1700 OWENS STREET, STE 500, SAN FRANCISCO CA 94158 |
| Column Group Gp, Lp |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Column Group L P |
10 percent owner |
1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
| Ponoi Management, Llc |
10 percent owner |
1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NRIX has been successfully added to your